UK approves XOANACYL, first drug in Europe to treat both iron deficiency and high phosphorus in CKD patients.

The UK’s MHRA has approved Averoa’s XOANACYL, an oral therapy for chronic kidney disease (CKD), targeting iron deficiency and high phosphorus levels. Approved via the International Recognition Procedure based on prior EU approval, it’s the first drug in Europe to treat both conditions simultaneously in adults. The drug aims to improve treatment adherence and outcomes for patients with CKD-related metabolic issues, affecting millions across the UK and Europe. Final EU approval remains pending, but a positive CHMP recommendation supports broader access.